The Multicenter KOALA Study: The Effects of Kaftrio After Lung Transplantation in Cystic Fibrosis

Purpose: Historically, the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator Kaftrio has been withheld from lung transplant (LTx) recipients with Cystic Fibrosis (CF) due to uncertainty regarding its efficacy, concerns about potential drug interactions and costs. The focus of Kaftrio therapy has been on pulmonary improvement instead of extrapulmonary benefits. However, considering the multi-systemic nature of CF, and the persistence of extrapulmonary symptoms after LTx, Kaftrio may also have potential relevant benefits for CF patients post-transplant.

Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , B. Luijk, M. Hellemons, K.A. Visser, C.M. Hansen, R. van der Meer, T. Gan, H. van der Vaart, O. Akkerman, W.N. Steenhuis, H.G. Heijerman, E.A. Verschuuren Source Type: research